Trajan Group Holdings (ASX:TRJ) - Share price, News & Analysis

TRJ fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	4/6
Past Performance	1/6
Financial Health	4/6
Dividends	0/6

TRJ Overview

Rewards

Trading at 16.2% below our estimate of its fair value

Earnings are forecast to grow 36.18% per year

Risk Analysis

Large one-off items impacting financial results

Profit margins (2.5%) are lower than last year (3.6%)

Trajan Group Holdings Competitors

Thermo Fisher Scientific

NYSE:TMO

US$231.3b

Danaher

NYSE:DHR

US$217.2b

Agilent Technologies

NYSE:A

US$46.9b

Price History & Performance

Summary of all time highs, changes and price drops for Trajan Group Holdings
Historical stock prices
Current Share Price	AU$3.00
52 Week High	AU$1.82
52 Week Low	AU$3.60
Beta	0
1 Month Change	-9.09%
3 Month Change	12.78%
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	51.52%

Shareholder Returns

	TRJ	AU Life Sciences	AU Market
7D	2.4%	-1.4%	0.9%
1Y	n/a	-4.8%	20.2%

Return vs Industry: Insufficient data to determine how TRJ performed against the Australian Life Sciences industry.

Return vs Market: Insufficient data to determine how TRJ performed against the Australian Market.

Price Volatility

Is TRJ's price volatile compared to industry and market?
TRJ volatility
TRJ Beta	0
Industry Beta	0.95
Market Beta	1

Stable Share Price: TRJ is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: Insufficient data to determine TRJ's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2011	432	Stephen Tomisich	https://www.trajanscimed.com

Trajan Group Holdings Limited develops, manufactures, and sells analytical and life science products and devices in Australia, New Zealand, Malaysia, Japan, the Americas, Europe, the Middle East, and Africa. It offers analytical, pathology, and sampling products, as well as automation systems for the analysis of biological, food, and environmental samples. The company also provides nutrition testing solutions for pathology laboratories, research and clinical trials, personalized nutrition, corporate wellness, and health insurance.

Trajan Group Holdings Fundamentals Summary

How do Trajan Group Holdings's earnings and revenue compare to its market cap?
TRJ fundamental statistics
Market Cap	AU$389.71m
Earnings (TTM)	AU$1.88m
Revenue (TTM)	AU$76.57m

207.3x

P/E Ratio

5.1x

P/S Ratio

Is TRJ overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
TRJ income statement (TTM)
Revenue	AU$76.57m
Cost of Revenue	AU$48.08m
Gross Profit	AU$28.48m
Expenses	AU$26.60m
Earnings	AU$1.88m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)	0.014
Gross Margin	37.20%
Net Profit Margin	2.46%
Debt/Equity Ratio	11.0%

How did TRJ perform over the long term?

See historical performance and comparison

Valuation

Is Trajan Group Holdings undervalued compared to its fair value and its price relative to the market?

16.2%

Undervalued compared to fair value

Share Price vs. Fair Value

Below Fair Value: TRJ (A$3) is trading below our estimate of fair value (A$3.58)

Significantly Below Fair Value: TRJ is trading below fair value, but not by a significant amount.

Price To Earnings Ratio

PE vs Industry: TRJ is poor value based on its PE Ratio (207.3x) compared to the Global Life Sciences industry average (46x).

PE vs Market: TRJ is poor value based on its PE Ratio (207.3x) compared to the Australian market (19.8x).

Price to Earnings Growth Ratio

PEG Ratio: TRJ is poor value based on its PEG Ratio (5.7x)

Price to Book Ratio

PB vs Industry: TRJ is overvalued based on its PB Ratio (5.9x) compared to the AU Life Sciences industry average (4.9x).

Future Growth

How is Trajan Group Holdings forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

36.2%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: TRJ's forecast earnings growth (36.2% per year) is above the savings rate (1.9%).

Earnings vs Market: TRJ's earnings (36.2% per year) are forecast to grow faster than the Australian market (11.7% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: TRJ's revenue (11% per year) is forecast to grow faster than the Australian market (5.5% per year).

High Growth Revenue: TRJ's revenue (11% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: TRJ's Return on Equity is forecast to be low in 3 years time (12.2%).

Past Performance

How has Trajan Group Holdings performed over the past 5 years?

25.8%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: TRJ has a large one-off gain of A$1.9M impacting its June 30 2021 financial results.

Growing Profit Margin: TRJ's current net profit margins (2.5%) are lower than last year (3.6%).

Past Earnings Growth Analysis

Earnings Trend: TRJ's earnings have grown significantly by 25.8% per year over the past 5 years.

Accelerating Growth: TRJ's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: TRJ had negative earnings growth (-27.9%) over the past year, making it difficult to compare to the Life Sciences industry average (59.8%).

Return on Equity

High ROE: TRJ's Return on Equity (2.8%) is considered low.

Financial Health

How is Trajan Group Holdings's financial position?

Financial Position Analysis

Short Term Liabilities: TRJ's short term assets (A$78.5M) exceed its short term liabilities (A$24.1M).

Long Term Liabilities: TRJ's short term assets (A$78.5M) exceed its long term liabilities (A$9.2M).

Debt to Equity History and Analysis

Debt Level: TRJ's debt to equity ratio (11%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if TRJ's debt to equity ratio has reduced over the past 5 years.

Debt Coverage: TRJ's debt is well covered by operating cash flow (129.5%).

Interest Coverage: Insufficient data to determine if TRJ's interest payments on its debt are well covered by EBIT.

Balance Sheet

Dividend

What is Trajan Group Holdings's current dividend yield, its reliability and sustainability?

Dividend Yield vs Market

Notable Dividend: Unable to evaluate TRJ's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate TRJ's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if TRJ's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if TRJ's dividend payments have been increasing.

Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of TRJ's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.

Next Steps

Explore strong dividend paying companies in the Pharmaceuticals & Biotech industry.

Management

How experienced are the management team and are they aligned to shareholders interests?

AU$520k

CEO Compensation

CEO

Stephen Tomisich

no data

Tenure

AU$520,434

Compensation

Mr. Stephen Tomisich serves as Chief Executive Officer, Managing Director and Director at Trajan Group Holdings Limited. Mr. Tomisich serves as Chief Executive Officer and Director at Trajan Scientific & M...

CEO Compensation Analysis

Compensation vs Market: Stephen's total compensation ($USD386.28K) is below average for companies of similar size in the Australian market ($USD556.28K).

Compensation vs Earnings: Stephen's compensation has been consistent with company performance over the past year.

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: TRJ only recently listed within the past 12 months.

Data	Last Updated (UTC time)
Company Analysis	2021/10/18 15:40
End of Day Share Price	2021/10/18 00:00
Earnings	2021/06/30
Annual Earnings	2021/06/30

Market Cap

7D

1Y

Updated

Data